News

15th October 2019 by

Headline Results of MTX110 Phase I DIPG Study

Phase II Dose Confirmed and Encouraging Survival Data Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, is pleased …

25th March 2021

MTX110 Update & Headline Results for 2020

11th December 2020

MTX110 Programmes to be presented at ISPNO 2020

9th December 2020

UK Parliament Highlights Need for New DIPG Treatments

24th November 2020

MTX110 presented at 2020 Annual SNO Conference

27th July 2020

UK Placing to Raise £5.0 million

21st July 2020

Collaboration for the Q-Sphera platform

8th June 2020

Research collaboration with Dr Reddy’s

24th October 2019

Midatech's MTX110 Receives Orphan Designation for DIPG

15th October 2019

Headline Results of MTX110 Phase I DIPG Study

Publications

14th December 2020

High dose MTX110 (soluble panobinostat) safely administered into the fourth ventricle in a …

Download
14th December 2020

1PNOC015: An Open Label Single Arm Study of MTX110 Delivered by Convection-enhanced Delivery (CED) …

Download
14th December 2020

A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of …

Download
24th November 2020

Conlon: Efficacy of soluble panobinostat (MTX110) in preclinical models of adult glioblastoma

Download
24th November 2020

PNOC015: An Open Label Single Arm Study of MTX110 Delivered by Convection-enhanced Delivery (CED) …

Download
1st June 2018

Singleton et al: The distribution, clearance, and brainstem toxicity of panobinostat administered …

Download
18th March 2017

Printing Particles: Printing particles: A high-throughput technique for the production of uniform, …

Download

Other areas

technology

pipeline

partners